USA - NYSE:BDX - US0758871091 - Common Stock
The current stock price of BDX is 185.83 USD. In the past month the price increased by 0.67%. In the past year, price decreased by -21.96%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.42 | 220.78B | ||
| ISRG | INTUITIVE SURGICAL INC | 63.47 | 195.91B | ||
| BSX | BOSTON SCIENTIFIC CORP | 34.27 | 149.82B | ||
| SYK | STRYKER CORP | 29.71 | 145.96B | ||
| MDT | MEDTRONIC PLC | 16.94 | 120.15B | ||
| IDXX | IDEXX LABORATORIES INC | 53.36 | 51.27B | ||
| EW | EDWARDS LIFESCIENCES CORP | 29.61 | 44.68B | ||
| RMD | RESMED INC | 27.17 | 37.87B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16.77 | 35.68B | ||
| PHG | KONINKLIJKE PHILIPS NVR- NY | 17.26 | 27.76B | ||
| DXCM | DEXCOM INC | 41.37 | 27.58B | ||
| STE | STERIS PLC | 25.24 | 23.71B |
Becton, Dickinson & Co. is a global medical technology company, which engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. The company is headquartered in Franklin Lakes, New Jersey and currently employs 74,000 full-time employees. The firm is engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, and more. Its BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. The BD Medical segment consists of various business units, including medication delivery solutions, medication management solutions, advanced monitoring, and pharmaceutical systems. Its BD Life Sciences segment provides products for the collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. Its BD Interventional segment provides vascular, urology, oncology and surgical specialty products.
BECTON DICKINSON AND CO
One Becton Drive
Franklin Lakes NEW JERSEY 07417 US
CEO: Thomas E. Polen
Employees: 74000
Phone: 12018476800
Becton, Dickinson & Co. is a global medical technology company, which engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. The company is headquartered in Franklin Lakes, New Jersey and currently employs 74,000 full-time employees. The firm is engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, and more. Its BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. The BD Medical segment consists of various business units, including medication delivery solutions, medication management solutions, advanced monitoring, and pharmaceutical systems. Its BD Life Sciences segment provides products for the collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. Its BD Interventional segment provides vascular, urology, oncology and surgical specialty products.
The current stock price of BDX is 185.83 USD. The price decreased by -0.38% in the last trading session.
BECTON DICKINSON AND CO (BDX) has a dividend yield of 2.23%. The yearly dividend amount is currently 3.8.
BDX has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
The next ex-dividend date for BECTON DICKINSON AND CO (BDX) is September 8, 2025.
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on BDX.
BECTON DICKINSON AND CO (BDX) currently has 74000 employees.
ChartMill assigns a technical rating of 3 / 10 to BDX. When comparing the yearly performance of all stocks, BDX is a bad performer in the overall market: 81.88% of all stocks are doing better.
ChartMill assigns a fundamental rating of 5 / 10 to BDX. BDX has an excellent profitability rating, but there are concerns on its financial health.
Over the last trailing twelve months BDX reported a non-GAAP Earnings per Share(EPS) of 14.27. The EPS increased by 11.75% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 7.51% | ||
| ROA | 2.93% | ||
| ROE | 6.3% | ||
| Debt/Equity | 0.69 |
18 analysts have analysed BDX and the average price target is 221.8 USD. This implies a price increase of 19.36% is expected in the next year compared to the current price of 185.83.
For the next year, analysts expect an EPS growth of 10.38% and a revenue growth 8.43% for BDX